Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Study Type: Treatment
Phase: II/III
NCTID: NCT01810913
Principal Investigator:
Chris Lominska
A Phase I/II, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
A Phase 1 Study of SGN-B6A-001 in Advanced Solid Tumors
A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD
A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT06050252
Principal Investigator:
Raed Al-Rajabi
A Phase II Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma GOLSEEK-2
Study Type: Treatment
Phase: II
NCTID: NCT06425302
Principal Investigator:
Marc Hoffmann
A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy SIRT using SIR-Spheres Y-90 resin microspheres on duration of response DoR and objective response rate ORR in unresectable hepatocellular carcinoma HCC patients DOORwaY90 Study
Study Type: Treatment
Phase: Device
NCTID: NCT04736121
Principal Investigator:
Zachary Collins
A Phase 2 Study of Veliparib ABT-888 and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma HGG without H3 K27M or BRAFV600 Mutations
Study Type: Treatment
Phase: II
NCTID: NCT03581292
Principal Investigator:
Kevin Ginn
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization TACE in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma EMERALD-1
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head Neck Squamous Cell Carcinoma HNSCC
Study Type: Other
Phase: N/A
NCTID: NCT06163534
Principal Investigator:
Prakash Neupane